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Abstract
Germline mutation of the BRCA1 associated protein-1 (BAP1) gene has been linked to uveal melanoma, mesothelioma,
meningioma, renal cell carcinoma and basal cell carcinoma. Germline variants have also been found in familial cutaneous
melanoma pedigrees, but their contribution to sporadic melanoma has not been fully assessed. We sequenced BAP1 in 1,977
melanoma cases and 754 controls and used deubiquitinase assays, a pedigree analysis, and a histopathological review to as-
sess the consequences of the mutations found. Sequencing revealed 30 BAP1 variants in total, of which 27 were rare (ExAc al-
lele frequency<0.002). Of the 27 rare variants, 22 were present in cases (18 missense, one splice acceptor, one frameshift and
two near splice regions) and five in controls (all missense). A missense change (S98R) in a case that completely abolished
BAP1 deubiquitinase activity was identified. Analysis of cancers in the pedigree of the proband carrying the S98R variant and
in two other pedigrees carrying clear loss-of-function alleles showed the presence of BAP1-associated cancers such as renal
cell carcinoma, mesothelioma and meningioma, but not uveal melanoma. Two of these three probands carrying BAP1 loss-
of-function variants also had melanomas with histopathological features suggestive of a germline BAP1 mutation. The re-
maining cases with germline mutations, which were predominantly missense mutations, were associated with less typical
pedigrees and tumours lacking a characteristic BAP1-associated histopathological appearances, but may still represent less
penetrant variants. Germline BAP1 alleles defined as loss-of-function or predicted to be deleterious/damaging are rare in
cutaneous melanoma.
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Introduction
Genome-wide association studies (GWAS) have now firmly
identified twenty loci as linked to sporadic melanoma develop-
ment in the general population, with genes at these loci includ-
ing regulators of telomere length and function such as TERT,
regulators of the cell cycle such as CDKN2A, and genes involved
in pigmentation and the control of naevus count (1,2).
Additionally, studies in melanoma-prone families have found
inactivating variants in CDKN2A (3) and CDK4 (4), and more re-
cently, activating variants in the promoter of TERT (5,6). Loss-of-
function variants in the protection of telomeres 1 (POT1) gene
(7,8), and other members of the shelterin complex (9), have also
been found. Collectively, these findings indicate that strong and
weakly penetrant variants influencing the same genes or biolo-
gical pathways may contribute to disease development in famil-
ial and sporadic melanoma, respectively.
The BAP1 protein was originally identified because of its
interaction with the protein product of the breast cancer sus-
ceptibility gene BRCA1 (10). BAP1 is a 80 kD protein of 729 amino
acids, carrying a ubiquitin C-terminal hydrolase (UCH) domain
at its N-terminus (10). Members of the UCH family play a role in
a vast array of cellular processes by cleaving ubiquitin or ubiqui-
tin conjugates from larger substrates. Established roles in the
deubiquitination of histones, the regulation of the cell cycle,
DNA repair and transcription have been identified for BAP1, and
established substrates for BAP1 include histone H2A and HCF-1
(11,12).
The BAP1 gene was first reported to be somatically mutated
in poor-prognosis uveal melanoma in 2010 (13), with one of the
uveal melanoma patients described in this study found to carry
a truncating germline variant. Subsequently, it was recognised
that germline BAP1 mutations are associated with a risk of dis-
parate cancers such as lung cancer, meningioma (14), meso-
thelioma (15), and renal cell carcinoma (16), with a recent pan-
cancer analysis revealing that BAP1 is significantly enriched for
somatic truncating mutations across a range of tumour types
(17). Intriguingly, while germline loss of Bap1 in the mouse re-
sults in embryonic lethality, somatic loss has been associated
with the development of a myelodysplastic syndrome (18), a
disease not normally associated with loss of BAP1 in humans.
Thus, mutation of BAP1, either somatically or in the germline, is
associated with a range of cancers, and the biological effects of
BAP1 loss are likely to manifest through a range of downstream
pathways (12,19).
Wiesner et al first reported a characteristic clinical and histo-
pathological appearance of melanocytic lesions in two families
with inherited BAP1 mutations, and showed somatic loss of the
wildtype allele in these tumours (20). The mutation carriers in
that study developed multiple, pink melanocytic lesions from
the second decade, which had an innocuous clinical appearance
but were quite remarkable at a histopathological level. At low
power, the lesions tended to have a symmetrical dermal archi-
tecture, with notable sparing of the epidermis. At higher magni-
fication, nuclear pleomorphism was prominent and
melanocytes could be largely categorised into two distinct
groups: epithelioid melanocytes with copious amounts of cyto-
plasm, and a flanking population of smaller ‘naevoid’ cells with
hyperchromatic nuclei. Some lesions were regarded as benign,
while others were deemed to be of ‘uncertain malignant poten-
tial’ due to high cellularity, marked nuclear pleomorphism or
chromosomal abnormalities, and were treated as melanoma.
BAP1 immunohistochemistry revealed nuclear staining in the
naevoid cells but loss of nuclear BAP1 staining within the
epithelioid component, suggesting that this could be a potential
marker of malignant progression. Subsequent reports have pro-
vided further evidence of these findings (21–24). Relatively little
is known about the appearance of primary cutaneous melano-
mas proven to metastasise in these families. One report how-
ever, described cytological findings typical of melanocytic
lesions from germline BAP1 mutation carriers, including the
presence of both epithelioid and naevoid-like cells except that
there was no sparing of the dermo-epidermal junction (25). A
biological spectrum of melanocytic lesions was proposed by
Wiesner et al, ranging from clearly benign to ‘potentially malig-
nant’, however, it can be difficult to define where a particular le-
sion lies within these boundaries. Notably, similar histological
appearances have been recorded for tumours with either som-
atic or germline BAP1 mutations (26).
Here we report germline mutations of the BAP1 gene in a
sample of 1977 melanoma patients and 754 controls ascertained
from the UK population as part of the Leeds Melanoma Case-
Control Study (27). We also performed an evaluation of cancer
incidence in BAP1 variant carriers and their families, and esti-
mated the degree to which the histopathological features of pri-
mary tumours predict germline BAP1 variant status.
Results
Identification of BAP1 variants
A total of 30 variants were identified, of which 27 were rare
(ExAC r0.3.1 allele frequency [AF]< 0.002) and three were com-
mon or polymorphisms (defined as variants with AF above this
threshold). Out of the 27 rare variants, 20 were protein-
changing and found in cases. These 20 variants can be classified
into missense (n¼ 18), truncating frameshift (n¼ 1) and invari-
ant splice acceptor (n¼ 1) mutations (Table 1, Fig. 1A,
Supplementary Material, Fig. 1). Of the seven remaining rare
variants, two fell near splice regions, found in one case each,
and five were found in controls (Table 1 and Fig. 1A). Of the
three common variants, one (S596G) with global ExAC AF¼ 0.
007154 was found in two cases, and the other two had similar
allele frequencies and were found in both cases and controls
(Table 1). Nine of the variants present in cases were predicted to
be deleterious by either the SIFT (28) or PolyPhen-2 (29) algo-
rithms (Table 1). All rare variants were confirmed by capillary
sequencing.
Deubiquitinase assays
Since the primary role of BAP1 is as a deubiquitinase, we asked
if the mutations identified influence BAP1 enzymatic activity
(Fig. 1B). To do this, we generated cDNA constructs in a
pcDNA3.1 expression vector, each carrying a different BAP1 mis-
sense or frameshift variant and transfected these into BAP1-
null H226 cells (Supplementary Material, Fig. 2A and B). We also
generated a wildtype (WT) BAP1 cDNA expression vector as a
control. All protein-changing variants in both cases and con-
trols were tested with the exception of R728H found in a control,
the missense alleles E406A, T613M and T613A, and the splice ac-
ceptor variant Chr3: 52442623 C/T (in intron 3–4), which were
found in cases and identified in a second round of sequencing
(Table 1, Fig. 1A, Supplementary Material, Fig. 2C). Western blot-
ting for BAP1 revealed the expected size shift of BAP1 in the
presence of the covalent electrophilic activity probe HA-Ub-
VME. A truncating frameshift mutant that disrupts BAP1 at
codon 618 (Chr3: 52437191 -/A, P618fs) produced two bands
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inconsistent with the expected size shift seen with the WT BAP1
cDNA construct. The reason why this construct produced two
bands was unclear. Since the P618fs construct contains cDNA
sequence downstream of the frameshift we postulated that
these two bands could be the result of transcriptional read-
through. We therefore generated an additional construct
(P618fs (*)) in which this C-terminal sequence was deleted and
obtained the same result (Supplementary Material, Fig. 2C).
Thus, it appears that these bands represent dimers or a cleav-
age product. In addition to the frameshift mutation, we also
identified a missense variant (S98R) falling into the UCH domain
that completely abolished deubiquitinase activity (Figs 1 and 2).
All of the other constructs appeared similar to WT, with only
modest changes in deubiquitinase activity (Fig. 1B). It should be
noted, however, that the assay we used will only detect large ef-
fects (loss-of-function), so subtle changes in activity might be
missed. Further, it is possible that some of the mutations we
identified influence BAP1 function by mechanisms that do not
involve its deubiquitinase activity. Interestingly, analysis of a
structural homology model based on UCHL5, the most closely
Figure 1. Protein-changing BAP1 variants in sporadic melanoma. (A) Protein-changing variants (predicted to be missense, cause a frameshift, or fall in a splice acceptor
site) identified by sequencing sporadic melanoma patients are shown above a protein structure domain model. The protein domain model was derived from (37).
Variants found in controls are shown below the model (blue). Loss-of-function variants are shown in green, and a polymorphism is shown in red. (B) Deubiquitinase ac-
tivity assays to assess the effect of protein-changing mutations in part A (above) on BAP1 enzymatic activity. Blue arrows denote mutants showing a profound effect
on BAP1 function.
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related protein to BAP1 (30), shows that position S98 is in close
proximity to the catalytic core, and a cross species analysis re-
veals that this amino acid is highly conserved throughout verte-
brates (Fig. 2).
Analysis of BAP1 variants in cases and controls
Alleles classified as group 1, 2 and 3 were found in 23 cases
(1.2%) while five controls (0.7%) had mutations with the same
severity as classified by SIFT/PolyPhen-2 (Table 1). This differ-
ence is not statistically significant because of the rareness of
these variants (Fisher’s Exact Test, P¼ 0.294). Group 1 alleles
were found in 3/1,977 cases (and 0/754 controls); these three
definite loss-of-function variants were S98R, a frameshift and a
splice acceptor variant (Fig. 1A and Table 1). Group 2 alleles
were found in 0.3% of cases, these types of alleles were also
found at the same frequency in controls (P¼ 1.00). Group 3 vari-
ants were found in 14 cases (15 variants among 14 cases; 0.7%)
with three controls having similarly classified variants (0.4%;
P¼ 0.43; Fisher’s Exact Test). For both of the two common poly-
morphisms (Group 4), there was no evidence of major differ-
ences between cases and controls (P¼ 1.0 for 3:52437424 and
P¼ 0.21 for 3:52436441). This study therefore suggests that com-
plete loss-of-function germline BAP1 mutations underlie sus-
ceptibility to cutaneous melanoma in 0.2% of the population-
ascertained melanoma cases in the UK. Even when variants
defined by SIFT and PolyPhen-2 as possibly damaging or dele-
terious are also considered (n¼ 9, discussed below) the overall
frequency of BAP1 mutations remains low (<1%) (Table 1).
Pedigree analyses of BAP1 loss-of-function variant
carriers
Previous reports have defined a spectrum of malignancies asso-
ciated with loss-of-function germline variants of BAP1 (31). In
family 1 (carrying the frameshift variant P618fs, Table 1 and Fig.
3A) we observed a second case of melanoma, a first-degree rela-
tive with bladder cancer and a second-degree relative with
mesothelioma. In family 2 (carrying S98R, Fig. 3B), the proband
had additionally presented with basal cell carcinomas (BCC),
and a further case of melanoma was observed in the family, in
addition to two cases of stomach cancer, and one each of renal
cancer and non-Hodgkin’s lymphoma. In family 3 (carrying the
splice acceptor variant in intron 3–4, Fig. 3C), a second case of
melanoma was observed in addition to a case with a malignant
blue naevus and meningioma, and one individual with meso-
thelioma. In this family, a case of STUMP (Spitzoid Tumour of
Uncertain Malignant Potential) was also diagnosed in a young
adult. A histopathological description of lesions from members
of this pedigree has been published previously (32). Thus, all
three of the probands had pedigrees consistent with the
described germline cancer predisposition syndrome associated
with loss-of-function BAP1 alleles.
Pedigree analyses of other potentially deleterious BAP1
variant carriers
In addition to the three families with clear loss-of-function
BAP1 mutations described, there were six families with BAP1
variants that were predicted to be deleterious by SIFT/PolyPhen-
2 (Group 2 [pedigrees 4–9], Table 1). Pedigrees for three of these
families, for which there was sufficient information available
for family history, are illustrated in Fig. 3D–F. The proband in
pedigree 4 (Fig. 3D), carrying the R150C variant, had a history of
melanoma, BCC and lymphoma and had first-degree relatives,
each with a history of one of the following cancers: BCC, leukae-
mia and uterine cancer. In pedigree 5 (Fig. 3E), in which the pro-
band carried an R548H missense mutation, there was a case of
stomach cancer in a first-degree relative and of uterine cancer
in a second-degree relative. In pedigree 6 (Fig. 3F), each of the
proband’s parents had a history of either BCC or colon cancer.
The proband from this pedigree carried an R264T missense mu-
tation. Of the remaining three individuals with predicted haz-
ardous BAP1 mutations, each carrying either A130V, S292C or
Y418C missense mutations, there was limited information
available for family history and thus their pedigrees are not
shown. There was no known family history of cancer in these
pedigrees apart from one case of lung cancer in a first-degree
relative in their 9th decade.
We next asked if a histopathological analysis of the primary
melanoma in the proband (indicated by an arrow in each pedi-
gree; Fig. 3) had features reported in the literature as being sug-
gestive of the atypical melanocytic tumours of germline BAP1
mutation carriers (Fig. 4).
Figure 2. Location and conservation of the S98R BAP1 mutation. (A) Shown is a structural homology model of the BAP1 related protein UCHL5 and the position of the
catalytic triad and of key residues including S98 and R114, which are depicted as the mutated residues found in this study. (B) Shown is the conservation of position 98
in BAP1 across vertebrate evolution.
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Histopathological analysis of tumours from BAP1 loss-
of-function variant carriers
Here, we discuss in detail the melanocytic lesions identified in
the three probands carrying confirmed loss-of-function variants
(Fig. 3A–C). Primary melanomas from each of the probands are
shown in Fig. 4A–C. Concerning the proband in pedigree 1
(Fig. 4A), the melanocytic proliferation was predominantly der-
mal, composed of pleomorphic melanocytes, many of which
contained hyperchromatic nuclei. Multi-nucleated melanocytes
(black arrow) and intranuclear pseudoinclusions (red arrows)
were also noted. This melanoma had a Breslow thickness of
1.5mm, without evidence of ulceration, and it resembled the
Figure 3. Pedigrees of BAP1 variant carriers identified from a sporadic melanoma cohort. The probands are indicated with an arrow. Black diamonds refer to individuals
with a diagnosis of melanoma. Grey refers to other cancers. ‘? Site’ refers to a case where the site is unknown. (A) Family of the proband with the P618fs variant.
(B) Family of the proband with the disruptive S98R variant. (C) Family of the proband with the splice acceptor variant. The patient with a Spitzoid Tumour of Uncertain
Malignant Potential (STUMP) is indicated in red. An individual with a malignant blue naevus and meningioma is shown in blue. (D–F) Pedigrees of three other families
carrying variants predicted to be deleterious by SIFT/Poly-Phen 2. MM: Malignant melanoma; NHL: Non-Hodgkin’s lymphoma; BCC: Basal cell carcinoma; Leuk:
Leukaemia. Approximate ages of onset are provided where available.
Figure 4. Histology of tumors from BAP1 probands. (A) Histopathological findings (x20) show an intradermal melanocytic lesion composed of pleomorphic melanocytes
with abundant cytoplasm, many of which contain hyperchromatic nuclei. The dermo-epidermal junction (DEJ) is relatively spared. Multi-nucleated melanocytes (black
arrow) and intranuclear pseudoinclusions (red arrows) are noted within this melanoma. (B) Histopathological findings (x10) show a melanoma with a predominantly
spindled appearance. (C) There is an asymmetrical melanocytic proliferation composed of pleomorphic melanocytes, arranged in nests at the DEJ and extending into
the dermis (x20). Some melanocytes have an epithelioid appearance with prominent nucleoli (thick black arrow), while others have hyperchromatic nuclei (red arrow).
Bi-nucleated melanocytes are present (thin black arrow).
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reported features of melanocytic lesions found in BAP1 muta-
tion carriers, being distinctly dermal in silhouette and com-
posed of pleomorphic, epithelioid melanocytes. Therefore, this
lesion could be readily recognized as consistent with the pheno-
type of a BAP1-associated melanocytic lesion. The proband in
pedigree 2 was diagnosed with a 0.7mm melanoma without ul-
ceration (Fig. 4B). This melanoma had prominent epidermal in-
volvement and was composed of spindle-shaped melanocytes.
Given that the majority of published melanoma cases in BAP1
families consist of epithelioid rather than spindled melano-
cytes, this histopathological appearance would be unlikely to
alert a pathologist to the presence of a BAP1 mutation, not being
remarkably different from melanomas seen among BAP1 wild-
type individuals. The proband in pedigree 3 was diagnosed with
a lesion containing dermal melanocytes that showed nuclear
pleomorphism, some of which had an epithelioid appearance,
whilst others had hyperchromatic nuclei (Fig. 4C). Bi-nucleated
melanocytes were also noted. This melanoma was 2.0mm in
thickness. More subtle changes, such as the presence of multi-
nucleated melanocytes and intranuclear pseudoinclusions
could be identified at higher magnification within melanomas
from the probands in pedigrees 1 and 3 (Fig. 4A). Such changes
have previously been reported in a range of melanocytic lesions
and are not known to be unique to BAP1 mutant tumours (33),
although they have been reported to be prominent within mela-
nocytic lesions from BAP1 syndrome families (23,32). In sum-
mary, two of these three probands had a melanoma that
demonstrated some features of a pathogenic germline BAP1
mutation and were most prominent in the proband in family 1.
Several other melanocytic lesions were available for assessment
in pedigree 3 and have previously been reported (32).
Analysis of all BAP1 variant carrier cases
The median age at diagnosis of melanoma was 57 years in cases
carrying no variant or a benign variant in BAP1, compared to 49
years in cases within the ‘predicted deleterious’ group (Table 1).
The observed difference in age was not statistically significant
(P¼ 0.7, Kruskal-Wallis test).
There were very few cases of mesothelioma or meningioma
within the cohort, so these data are based upon small numbers,
but statistical analysis revealed that cases were more likely to
carry a deleterious BAP1 variant compared to no variant if there
was a history of meningioma or mesothelioma in the proband
or their pedigree (Table 2; P¼ 0.02, OR¼ 58.3 (95% CI 1.1–670.5)
and P¼ 3  106, OR¼ 233 (95% CI 26.7–1660.1), respectively).
Cases with a positive family history of BCC were also more
likely to carry a predicted deleterious variant (P¼ 0.02, OR 7.7
(95% CI 1.2–36.5). It was notable that no cases with a predicted
deleterious variant had a personal or family history of ocular
melanoma.
Interestingly, cases with the ‘BAP-like phenotype (in the fam-
ily)’ were more likely to carry a predicted deleterious variant com-
pared to none (Table 2; P¼ 0.006, OR 8.2 (95% CI 1.6–38.4)). A
central pathology review for the presence or absence of BAP-like
histology in the proband’s melanoma (Table 2, ‘BAP-like histology
present (in the proband’s melanoma)’) was available for just over
one third of probands for which a family history was available
(n¼ 713/1,977; 36.1%). The presence of suggestive histological fea-
tures (‘BAP-like histology present (in the proband’s melanoma)’),
however, was not significantly predictive of a predicted deleteri-
ous BAP1 variant compared to no variant (Table 2; P¼ 0.1). There
was no significant relationship between a classical BAP1-like
histology in the proband’s melanoma and a personal or family
history of the individual BAP1-associated cancers, except for a
family history of mesothelioma (P¼ 0.02) or mesothelioma in the
pedigree overall (P¼ 0.03). Whilst two out of three of probands
with a loss-of-function BAP1 variant had BAP-like histology in the
proband’s melanoma, none of the remaining six cases classified
as ‘predicted deleterious’ had such features (not shown). It is pos-
sible that some variants that were not identified as loss-of-
function alleles by functional testing (deubiquitinase assays),
may still impair BAP1 function and predispose to cancer types
associated with the BAP1 syndrome phenotype.
Discussion
Germline mutations in BAP1 are rare, being present in<1% of
the population-ascertained melanoma cases in the UK. It has
been noted that high-penetrance variants found in melanoma-
prone families can also contribute to sporadic disease, for ex-
ample, germline mutations of CDKN2A have been identified in
around 2% of cases in European and Australian cohorts (34). As
such, we sought to determine the contribution of BAP1 variants
to sporadic melanoma, and here we present the most compre-
hensive such analysis to-date. We sequenced 1,977 melanoma
cases and 754 controls, identifying a total of 30 BAP1 variants.
Of these, 27 were rare and three were common or polymorph-
isms. Out of the 27 rare variants, 20 were protein-changing and
found in cases, two fell near splice regions (found in one case
each), and 5 were found in controls. Of the three common vari-
ants, one was found in two cases and the other two had similar
allele frequencies and were found in both cases and controls
(Table 1, Fig. 1A, Supplementary Material, Fig. 1).
Of the variants detected, three were clearly loss-of-function.
There was no alteration of deubiquitinase function detected
with the remaining six variants that were predicted to be dele-
terious by SIFT/Polyphen-2. The close relatives of the 9 pro-
bands carrying these predicted deleterious variants were an
estimated 8 times more likely to report a cancer previously
associated with BAP1 germline variants than among probands
without a BAP1 variant allele (Table 2); however, most of this
increase is due to the 3 families with loss-of-function mutations
who all reported a family history of BAP1-associated cancers
(mesothelioma, renal cancer). Excluding those 3 families, there
is an estimated 2-fold increased risk of a BAP1-associated can-
cer but this is no longer statistically significant (P¼ 0.43, data
not shown). It is possible therefore that some of the missense
variants identified influence BAP1 function subtly, at a level
below that which we can detect using the assay applied here.
Further mechanisms that these mutations may influence could
include protein turnover, secondary protein-protein inter-
actions, regulation of deubiquitinase activity in response to
stimuli, and protein localisation, which have not been formally
assessed here. Overall, less than 0.2% of melanoma cases had
identifiable loss-of-function BAP1 variants.
Regarding the three pedigrees in which a clear loss-of-
function BAP1 variant was identified (Table 1, Fig. 3A–C), their
family histories of cancer were suggestive of a deleterious BAP1
variant, although the reported cancers most strongly associated
with the mutation were mesotheliomas, meningiomas and BCC
rather than the uveal melanomas in which germline BAP1 mu-
tations were first reported (Fig. 3) (13). The remaining six pro-
bands with BAP1 variants predicted to be deleterious by SIFT or
PolyPhen-2 had equivocal pedigrees.
We examined the cancer history in BAP1 variant carrier
cases, comparing groups with predicted deleterious variants,
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benign variants, and no variants. The presence of a predicted
deleterious variant was associated with several observations
(Table 2): particularly a personal history of mesothelioma and a
family history of BCC, meningioma, mesothelioma or cutaneous
melanoma. The presence of a ‘BAP-like phenotype’ in the family
history highlights the importance of taking the extended pedi-
gree into account when assessing the risk of carrying a deleteri-
ous BAP1 variant. Notably most of the predicted deleterious/
possibly damaging variants we identified did not exert a signifi-
cant effect on deubiquitinase activity (Fig. 1B) suggesting that
weaker alleles, or variants that may influence BAP1 beyond its
role as a deubiquitinase, may underlie some of the cancer inci-
dence in mutation carriers. Also of note was the observation
that none of the cases with predicted deleterious variants had a
personal or family history of ocular melanoma.
Primary melanomas in 2/3 probands with clear loss of func-
tion mutations demonstrated some of the histopathological fea-
tures described in melanocytic lesions associated with a BAP1
mutation (Fig. 4). These families also had typical family histor-
ies of cancer (except that uveal melanomas were not seen).
None of the remaining six probands with BAP1 variants, pre-
dicted to be deleterious by SIFT or PolyPhen-2, had suggestive
histology and importantly, similar histological changes were
seen in a significant proportion of melanoma patients without a
germline BAP1 mutation. Our study therefore suggests that in
the absence of a family history of cancers such as mesotheli-
oma, or meningioma, the presence of histological changes
described in BAP1 mutated families is a poor predictor of a
germline BAP1 mutation. It may be that the histological changes
indicate other germline mutations or somatic changes in the
BAP1 pathway and further studies are required to determine the
biological basis of these histological variants.
The term ‘BAPomas’ is sometimes coined by pathologists to
denote melanocytic lesions with consistent histology that occur
within families with germline BAP1 mutations, which have ei-
ther benign behaviour or are of uncertain malignant potential.
As germline BAP1 mutations are relatively rare, and extensive,
long-term follow-up data are lacking, it is difficult to confidently
determine which lesions can be safely observed and which re-
quire more aggressive monitoring and treatment. Therefore, it
is important to establish a clinical history of change, combined
with the advice of an experienced dermatopathologist for
excised lesions.
We hope that this work presents a framework for consider-
ing the management of individuals found to carry germline
BAP1 mutations in the context of sporadic melanoma.
Materials and Methods
Ascertainment of cases and controls
The Leeds Melanoma Case-Control Study recruited 2,184 cases
and 513 population-based controls, predominantly from
Yorkshire, UK, as previously described (27). Of those recruited,
germline DNA was obtained from 1,977 cases and 488 control
participants (27), which was then used for sequencing. IRB (REC)
reference number 01/3/057. DNA from a further 266 controls
was obtained from Wellcome Trust Case Control Consortium
(WTCCC) samples bringing the total number of controls to 754.
Sequence analysis of BAP1
We used targeted capture to sequence BAP1, obtaining between
92 and 95% of all target bases in all samples covered with10x
high quality reads across all exons of the gene following map-
ping to the GRCh37 genome assembly. Variants were called
using samtools mpileup and annotated using the Variant Effect
Predictor (VEP) (35) in the canonical BAP1 transcript
(ENST00000460680). Variant calls were then filtered keeping po-
tentially disruptive variants for subsequent analyses (missense,
nonsense, and frameshift variants, and those near splice re-
gions and splice sites). All reported variants were successfully
validated by capillary sequencing.
Functional analysis of BAP1 variants
We transfected pcDNA3.1 constructs containing BAP1 variants
into H226 lung cancer cells and measured deubiquitinase activ-
ity using a HA-Ub-VME activity probe, as described previously
(36). These experiments were independently replicated a min-
imum of three times. For BAP1 Western blotting, we used the
antibody sc-28383 raised against amino acids 430–729 (c-ter-
minus). Western blotting and comparative genomic hybridiza-
tion were used to authenticate H226 cells confirming they are
BAP1 null (Supplementary Material, Fig. 2A and B).
Pedigree analysis
Participants in the Leeds Melanoma Case-Control Study (27)
were asked to list their family history of cancer at recruitment.
The protocol allowed the recruitment of first-degree relatives of
cases, but participation in family recruitment was dependent on
the willingness of the case to invite family members. Therefore,
the details provided were variable and pathological confirm-
ation of cancer diagnoses was possible only where family mem-
bers were also recruited. In several instances, multiple family
members were ascertained, so we selected the first recruited
case of melanoma for analysis. The exceptions were as follows:
where only one member of the family was tested, that melan-
oma case was included in the analysis; there was one family in
which two melanoma cases were independently ascertained
and both cases were therefore retained in the analysis.
Histological review
Five-micron histological sections were cut from primary melan-
oma formalin-fixed paraffin-embedded (FFPE) tumour blocks
and stained with haematoxylin and eosin (H&E). These H&E
sections were scanned using the Aperio AT2VR slide scanner.
Aperio ImageScope 12.0 was used for the histological review.
Several histopathological features have been associated with
melanocytic lesions from BAP1 carriers. These features are dis-
cussed in the introduction and were used to classify cases.
Analysis of cancer phenotypes in BAP1 variant carriers
We used the phenotypes of all BAP1 variant carrier cases to ex-
plore the influence of BAP1 alleles on cancer presentation. To do
this, we classified the BAP1 alleles into four groups based on like-
lihood of pathogenicity (Table 1, Supplementary Material, Fig. 1).
Cases carrying confirmed loss-of-function alleles were classified
into group 1 (n¼ 3) and those carrying variants predicted to be
hazardous by SIFT and/or PolyPhen-2 were classified as group 2
(n¼ 6). These were grouped together as ‘predicted deleterious’
(n¼ 9, Table 1, Supplementary Material, Fig. 1). Cases carrying
variants predicted to be benign by SIFT and PolyPhen-2 (n¼ 14,
as one case carries variants at both 3:52440269 and 3:52437206)
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were classified as group 3 and those carrying variants of uncer-
tain significance (n¼ 86, as one case carries variants at both
3:52436441 and 3:52437424) were classified as group 4. These
were grouped together as ‘Benign’ (n¼ 100). The rest of the mel-
anoma patient cohort who did not carry a variant were grouped
together and defined as ‘None’ (n¼ 1,868). This left us with nine
individuals defined as carrying a predicted deleterious variant,
100 defined as carrying a benign variant, and 1,868 with no vari-
ants in BAP1 (Tables 1 and 2). We assigned the same classifica-
tion to rare variants in controls but these samples were not used
in the comparisons shown in Table 2.
We defined a ‘BAP-like phenotype’ by combining informa-
tion recorded for cancers associated with BAP1 germline muta-
tions. A proband was deemed to have the ‘BAP-like phenotype
(in the proband)’ (Table 2) if he/she had a history of one or more
of the following cancers: renal, BCC, meningioma, mesotheli-
oma or ocular melanoma. Cutaneous melanoma was excluded
from this calculation, given that all probands already had a his-
tory of cutaneous melanoma. The ‘BAP-like phenotype (in the
family)’ was assigned in a similar way (Table 2) if a first- or
second-degree relative had a history of any of the aforemen-
tioned cancers (excluding a family history of cutaneous melan-
oma). The ‘BAP-like phenotype MM (in the family)’ (Table 2) was
analysed separately and was assigned if there was a positive
family history of cutaneous melanoma or any of the cancers
summarized by the ‘BAP-like phenotype (in the family)’. The
‘BAP-like phenotype (in the proband or family)’ category was
derived from the either the presence of the ‘BAP-like phenotype
(in the proband)’ or the ‘BAP-like phenotype (in the family)’ cate-
gories. Therefore, the ‘BAP-like phenotype MM (in the proband
or family)’ refers to the presence of either the ‘BAP-like pheno-
type (in the proband) or the ‘BAP-like phenotype MM (in the
family)’, i.e. the presence of a history of any of the following can-
cers in the proband or family: renal cancer, BCC, meningioma,
mesothelioma or ocular melanoma; or the presence of a family
history of cutaneous melanoma.
Statistical analysis
Statistical analyses were performed using STATAv14.0. The
Fisher’s exact test was used to assess the association between
the reported history of cancer and BAP1 variant categories
(Tables 1 and 2, Supplementary Material, Fig. 1), or the pres-
ence/absence of suggestive histology. Where the number of
cases was5 we used the Pearson’s Chi-squared test. The
Cornfield approximation was used to calculate odds ratios (OR)
and 95% confidence intervals (95% CI).
Supplementary Material
Supplementary Material is available at HMG online.
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